Format

Send to

Choose Destination
Pharmacogenet Genomics. 2009 Dec;19(12):911-22. doi: 10.1097/FPC.0b013e3283307cba.

Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs.

Author information

1
Department of Genetics, Gardner Hall, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.

Abstract

BACKGROUND:

Epilepsy, with a prevalence as high as 6%, is the most common neurological disorder in dogs. Although several antiepileptic drugs are in common use, in one-third of all epileptic dogs, adequate seizure control is not achieved with a single medication, and hence a combinatorial drug treatment must be adopted. Exploration of the genetic mechanisms involved in drug response may provide better treatment options for epileptic patients.

METHODS AND RESULTS:

A custom Illumina BeadChip was designed for high throughput genotyping of 384 single nucleotide polymorphisms in 30 genes involved in drug metabolism, drug targeting, and drug transport. A case-control association study of 125 epileptic dogs identified five genes with suggestive association to phenobarbital drug response: KCNQ3, P=0.0003; SNC2A2, P=0.0008; EPOX HYD, P=0.0005; ABCC4, P=0.0091; and GABRA2, P=0.0130. These associations are not significant after adjustment for multiple comparisons, but on functional grounds may tag strong candidate genes. The study was powered to detect alleles with at least 3.5-fold additive increases in responsiveness. A combined area under the curve value of 0.74 from receiver operating curve analysis also provides suggestive support for their consideration as canine pharmacogenetic markers.

CONCLUSION:

Further replication and assessment of breed specificity is required before these markers can be considered as predictive of responsiveness to phenobarbital in dogs.

PMID:
19841609
DOI:
10.1097/FPC.0b013e3283307cba
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center